Exagen Inc. (XGN) Stock Price & Analysis

Exagen Inc. (XGN) rose 2.62% to USD 4.31 as of June 10, 2026 at 07:38 UTC, according to Nexqual real-time market data.

XGN last closed at USD 4.2; the session ranged USD 4.15–4.49 on volume of 299,485 shares. Market capitalization is $104.13M, with a 52-week range of USD 2.59–12.23 (NGM). Source: Nexqual, June 10, 2026 at 07:38 UTC.

Key Statistics (as of June 10, 2026 at 07:38 UTC)

Technical Analysis (XGN)

Nexqual's technical model rates XGN "NEUTRAL" based on 3 bullish and 2 bearish signals across 123 daily candles, as of June 10, 2026 at 07:38 UTC.

Analyst Ratings (XGN)

Wall Street analysts rate XGN "None" based on 6 analysts, with a mean price target of USD 8.67 (range USD 8–10), per Nexqual as of June 10, 2026 at 07:38 UTC.

Earnings (XGN)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 07:38 UTC.

Financials & Fundamentals (XGN)

Source: Nexqual, June 10, 2026 at 07:38 UTC.

Financial Health Score (XGN)

Nexqual rates Exagen Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 07:38 UTC.

Ownership (XGN)

Source: Nexqual, June 10, 2026 at 07:38 UTC.

Leadership (XGN)

Exagen Inc. is led by John Aballi (age 40), CEO, President & Director, per Nexqual as of June 10, 2026 at 07:38 UTC.

Major Backers & Investors (XGN)

Notable institutional backers of Exagen Inc. include Balyasny Asset Management LP, Wexford Capital LP, Acadian Asset Management. LLC, according to Nexqual as of June 10, 2026 at 07:38 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 07:38 UTC.

From Exagen Inc.'s Latest SEC 10-K Filing (filed 2026-03-10)

Key Strengths & Strategy (as disclosed to the SEC)

• Our laboratory is certified for performance of high-complexity testing by the Centers for Medicare & Medicaid Services (CMS) in accordance with CLIA and is licensed by California and all states requiring out-of-state licensure, including the New York Department of Health (NYSDOH).
• The research projects we support are those that we believe will have a competitive advantage (such as using proprietary technology), a pathway for reimbursement and an established evidence development plan with sufficient market size.
• Our Proprietary Technologies We believe the competitive advantage for our testing products is supported by two core proprietary technologies: our AVISE ® Lupus platform, which incorporate Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE and a set of three biomarkers, the t-cell based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into our AVISE ® CTD product.
• We believe the availability of complement biomarkers combined with our proprietary algorithmic interpretations, as a support or replacement of standard C3 and C4 measures, is of great value for rheumatologists and their patients.

Partnerships

• We believe there is significant potential to capitalize on our proprietary technologies by integrating with commercially validated biomarkers to develop testing products with superior clinical utility, on our own or through collaboration with partners.
• We believe there is significant potential to enhance existing or develop new testing products with superior clinical utility, on our own or through collaboration with partners. ▪ Lupus Nephritis (LN) Biomarkers .

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:38 UTC. This page is informational and not investment advice.